1. Home
  2. CHCO vs VRDN Comparison

CHCO vs VRDN Comparison

Compare CHCO & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo City Holding Company

CHCO

City Holding Company

HOLD

Current Price

$143.01

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

Logo Viridian Therapeutics Inc.

VRDN

Viridian Therapeutics Inc.

HOLD

Current Price

$21.95

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHCO
VRDN
Founded
1957
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.1B
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
CHCO
VRDN
Price
$143.01
$21.95
Analyst Decision
Hold
Strong Buy
Analyst Count
2
14
Target Price
$132.50
$35.46
AVG Volume (30 Days)
78.0K
1.1M
Earning Date
04-23-2026
05-07-2026
Dividend Yield
2.87%
N/A
EPS Growth
13.18
N/A
EPS
4.55
N/A
Revenue
N/A
$5,706,000.00
Revenue This Year
$5.16
$13.73
Revenue Next Year
$3.12
$279.00
P/E Ratio
$31.45
N/A
Revenue Growth
N/A
N/A
52 Week Low
$113.21
$13.18
52 Week High
$148.99
$34.29

Technical Indicators

Market Signals
Indicator
CHCO
VRDN
Relative Strength Index (RSI) 43.14 46.44
Support Level $141.72 $21.40
Resistance Level $147.01 $23.84
Average True Range (ATR) 1.88 0.88
MACD -0.36 -0.24
Stochastic Oscillator 16.99 28.87

Price Performance

Historical Comparison
CHCO
VRDN

About CHCO City Holding Company

City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Share on Social Networks: